Rapid development of pancreatitis following reuse of 6-mercaptopurine.
A patient with Crohn's disease developed acute pancreatitis 4 h after retaking one 50 mg dose of orally administered 6-mercaptopurine (6-MP). All seven previously reported patients who were rechallenged with 50 mg or more of 6-MP developed pancreatitis within 48 h. These findings suggest that 6-MP can produce pancreatitis due to an idiosyncratic immune-mediated response. Patients with this complication should not reuse 6-MP.
Cappell
M S
MS
Division of Gastroenterology, University of Medicine of New Jersey-Robert Wood Johnson (Rutgers) Medical School, New Brunswick 08903-0019.
Das
K M
KM
D000328:Adult; D003424:Crohn Disease / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced*; D013997:Time Factors
D015122:Mercaptopurine